Domestic purchase status of ruxolitinib ointment and overseas purchase guide

Ruxolitinib ointment, this innovative drug branded asOpzelura, is gradually becoming a star product for the treatment of atopic dermatitis and non-segmental alopecia areata. Its core ingredient, ruxolitinib, is a selective Januskinase (JAK) 1/2 inhibitor. It effectively reduces inflammation by precisely blocking the JAK-STAT signaling pathway, bringing significant relief to patients from itching, redness and swelling. It is particularly worth mentioning that ruxolitinib ointment is the first JAK inhibitor approved by the FDA for the treatment of alopecia areata. It helps hair follicles recover and hair regenerates by regulating the immune system.

To use ruxolitinib ointment, patients only need to lightly apply the ointment to the affected area twice a day, which is easy to operate. However, due to its strong medicinal effect, you must follow medical advice when using it for a long time to ensure safety and avoid the risk of side effects.

Unfortunately, ruxolitinib ointment has not yet entered the domestic market, and patients cannot purchase it directly in domestic pharmacies. Faced with this gap, patients have no choice but to turn to overseas channels for help. Although overseas original drugs are effective, they are expensive, often exceeding 10,000 yuan. In contrast, generic drugs in Bangladesh are priced at a few hundred yuan and have ingredients similar to the original drugs, making them a cost-effective choice for many patients.

To sum up, ruxolitinib ointment has opened up a new treatment path for patients with atopic dermatitis and alopecia areata, especially for patients whose traditional treatments are ineffective. With the continuous expansion of global applications, we have reason to believe that ruxolitinib ointment will enter the domestic market in the near future and benefit more patients.